Form 4 for STOK Stoke Therapeutics, Inc.
Accepted 2025-01-02 00:00:00 ET · period of report 2024-12-30 · accession 0001415889-25-000084 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-01-02 | 2024-12-30 | STOK | Kaye Edward M. MD | CEO, Dir | M - OptEx | $0.6 | +35.0K | 96.9K | +57% | +$21.0K |
| D | 2025-01-02 | 2024-12-30 | STOK | Kaye Edward M. MD | CEO, Dir | M - OptEx | $0.00 | -35.0K | 567.8K | -6% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-12-30 | M | A | 35,000 | $0.6 | 96,885 | D | — | — | |
| 2 | Derivative | Employee Stock Option (Right to Buy) | 2024-12-30 | M | D | 35,000 | $0.00 | 567,801 | D | $0.6 · — to 2028-04-02 | 35,000 Common Stock | (F1) The option became fully vested as of October 17, 2022. |